{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:58:32Z","timestamp":1763348312221,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.canrad.2020.03.014","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T02:13:31Z","timestamp":1604283211000},"page":"892-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group"],"prefix":"10.1016","volume":"24","author":[{"given":"Y.","family":"Belkacemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hasbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Coraggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Chapet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Crehange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Guerif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Duberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Allouache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Clavere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Azria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2020.03.014_bib0235","first-page":"9","article-title":"Cancer statistics, 2014: cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2020.03.014_bib0240","doi-asserted-by":"crossref","first-page":"107-18","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2020.03.014_bib0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2020.03.014_bib0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0255","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0260","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.ju.0000112979.97941.7f","article-title":"The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer","volume":"171","author":"Laverdi\u00e8re","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0265","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S1470-2045(12)70084-0","article-title":"Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?","volume":"13","author":"Zumsteg","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.6004\/jnccn.2010.0010","article-title":"The 2010 NCCN clinical practice guidelines in oncology on prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2020.03.014_bib0275","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2020.03.014_bib0280","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.03.014_bib0285","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijrobp.2003.10.059","article-title":"A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy","volume":"59","author":"Chism","year":"2004","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0290","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2020.03.014_bib0295","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2020.03.014_bib0300","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2011.09.010","article-title":"Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden","volume":"61","author":"Van Hemelrijck","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0305","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.03.002","article-title":"Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists\u2013a nationwide population-based cohort study based on 2010-2013 French Health Insurance data","volume":"77","author":"Scailteux","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2020.03.014_bib0315","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eursup.2010.07.001","article-title":"Androgen-deprivation therapy in prostate cancer: a European Expert Panel Review","volume":"9","author":"Schulman","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.canrad.2020.03.014_bib0320","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0325","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.juro.2013.05.005","article-title":"Castration-resistant prostate cancer: AUA Guideline","volume":"190","author":"Cookson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0330","first-page":"151","article-title":"NCCN guidelines index table of contents","author":"Mohler","year":"2018","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.canrad.2020.03.014_bib0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2490-13-58","article-title":"Treatment patterns and characteristics of European patients with castration-resistant prostate cancer","volume":"13","author":"Sternberg","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0340","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0345","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0350","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-014-1813-1","article-title":"High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up","volume":"141","author":"Hou","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0355","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clon.2014.06.016","article-title":"Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses","volume":"26","author":"Schmidt-Hansen","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0360","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00066-007-2011-8","article-title":"Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?","volume":"183","author":"Roach","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0365","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/cncr.27857","article-title":"The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms","volume":"119","author":"Stoyanova","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2020.03.014_bib0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0375","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ctrv.2015.10.005","article-title":"Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)","volume":"41","author":"Sargos","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2020.03.014_bib0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2013.05.029","article-title":"Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection","volume":"109","author":"Abdollah","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0390","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2008.07.053","article-title":"Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era","volume":"74","author":"Nguyen","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0395","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijrobp.2010.01.068","article-title":"A new formula for prostate cancer lymph node risk","volume":"80","author":"Yu","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0400","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2013.07.041","article-title":"Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the radiation therapy oncology group 0126 prostate cancer trial","volume":"87","author":"Michalski","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0405","doi-asserted-by":"crossref","first-page":"e0154499","DOI":"10.1371\/journal.pone.0154499","article-title":"The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures","volume":"11","author":"Yu","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.canrad.2020.03.014_bib0410","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/820403","article-title":"The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada","volume":"2015","author":"Davis","year":"2015","journal-title":"J Oncol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0420","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2020.03.014_bib0425","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish Population-based Cohort Study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0430","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0435","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer: ADT and cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2020.03.014_bib0440","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease\u2013induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2020.03.014_bib0445","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2020.03.014_bib0450","unstructured":"A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease. Clinical Trials.gov, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02663908."},{"key":"10.1016\/j.canrad.2020.03.014_bib0455","unstructured":"Trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus gnrh agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. Clinical Trials.gov."},{"key":"10.1016\/j.canrad.2020.03.014_bib0460","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820302924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820302924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:32:55Z","timestamp":1761136375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321820302924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1278321820302924"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2020.03.014","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2020.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}